← Back to Search

Device

Brain Stimulation for Epilepsy

N/A
Recruiting
Led By Brian Lundstrom, MD, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at how brain stimulation can reduce epileptic seizures.

Who is the study for?
This trial is for individuals with focal epilepsy who experience at least two seizures per month and haven't found seizure control with at least two anti-seizure medications. Participants must be able to maintain their current medication regimen, understand consent in English, and keep a seizure diary.
What is being tested?
The study tests whether electrical stimulation applied to the scalp using ActivaDose II device can reduce the frequency and intensity of epileptic seizures. There are two levels of stimulation being tested: low (0.1 mA) and standard (2.0 mA).
What are the potential side effects?
Potential side effects may include discomfort or skin irritation where the electrodes are placed on the scalp, headache, fatigue, nausea, or tingling sensations during or after treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Seizure Count
Secondary study objectives
EEG interictal discharge frequency

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: tDCS Treatment B (High Amplitude)Experimental Treatment1 Intervention
Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The last treatment stimulation will be completed during the following 2-months.
Group II: tDCS Treatment A (Low Amplitude)Experimental Treatment1 Intervention
Subjects with focal epilepsy that is not well-controlled on anti-seizure medications will receive 2 different treatments periods, each lasting 2 months, of transcranial direct current stimulation (tDCS). The initial treatment stimulation will be completed during the first 2-months.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,343 Previous Clinical Trials
3,062,322 Total Patients Enrolled
22 Trials studying Epilepsy
1,051 Patients Enrolled for Epilepsy
Brian Lundstrom, MD, PhDPrincipal InvestigatorMayo Clinic

Media Library

ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05673915 — N/A
Epilepsy Research Study Groups: tDCS Treatment B (High Amplitude), tDCS Treatment A (Low Amplitude)
Epilepsy Clinical Trial 2023: ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) Highlights & Side Effects. Trial Name: NCT05673915 — N/A
ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05673915 — N/A
~0 spots leftby Dec 2024